KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Long-Term Debt Issuances (2016 - 2021)

Historic Long-Term Debt Issuances for Pfizer (PFE) over the last 11 years, with Q4 2021 value amounting to $997.0 million.

  • Pfizer's Long-Term Debt Issuances fell 8090.77% to $997.0 million in Q4 2021 from the same period last year, while for Dec 2023 it was $997.0 million, marking a year-over-year change of. This contributed to the annual value of $30.8 billion for FY2023, which is N/A changed from last year.
  • Latest data reveals that Pfizer reported Long-Term Debt Issuances of $997.0 million as of Q4 2021, which was down 8090.77% from $5.2 billion recorded in Q3 2020.
  • Pfizer's Long-Term Debt Issuances' 5-year high stood at $5.3 billion during Q2 2017, with a 5-year trough of $1.0 million in Q4 2017.
  • Its 5-year average for Long-Term Debt Issuances is $3.3 billion, with a median of $4.4 billion in 2019.
  • Its Long-Term Debt Issuances has fluctuated over the past 5 years, first crashed by 9998.32% in 2017, then tumbled by 7488.87% in 2020.
  • Over the past 5 years, Pfizer's Long-Term Debt Issuances (Quarter) stood at $1.0 million in 2017, then skyrocketed by 497300.0% to $5.0 billion in 2018, then dropped by 0.64% to $4.9 billion in 2019, then grew by 5.67% to $5.2 billion in 2020, then plummeted by 80.91% to $997.0 million in 2021.
  • Its last three reported values are $997.0 million in Q4 2021, $5.2 billion for Q3 2020, and $4.0 billion during Q2 2020.